Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to establish the safety and effectiveness of the Blazer Open-Irrigated radiofrequency ablation catheter for the treatment of drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.


Clinical Trial Description

The ZERO-AF trial is a prospective, multicenter, single blind, 1:1 randomized study. The trial is designed to demonstrate that the safety and effectiveness of the Blazer® Open-Irrigated Ablation Catheter are non-inferior to the safety and effectiveness of the control catheters, for the treatment drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation. The control catheters are open-irrigated radiofrequency ablation catheters that are approved in the United States for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01687166
Study type Interventional
Source Boston Scientific Corporation
Contact
Status Completed
Phase N/A
Start date October 2012
Completion date October 2016

See also
  Status Clinical Trial Phase
Completed NCT03539302 - INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT) Phase 2
Completed NCT01456949 - Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS) N/A